Paroxysmal Nocturnal Hemoglobinuria  >>  Soliris (eculizumab)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01412047: Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Completed
N/A
75
US, Europe, RoW
Alexion Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria, PNH
06/13
06/13
EMBRACE, NCT00438789: The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol

Approved for marketing
N/A
US
eculizumab
Alexion Pharmaceuticals
Hemoglobinuria, Paroxysmal
 
 
PREPARE, NCT04079257 / 2017-000089-31: The Pharmacokinetics and Pharmacodynamics of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed
N/A
27
Europe
Blood collection for measurement of eculizumab peak concentrations, blood collection
Radboud University Medical Center
Paroxysmal Nocturnal Hemoglobinuria, Eculizumab, PK-PD
07/22
07/22
NAP, NCT04671810: Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®

Completed
N/A
44
RoW
Elizaria®, Eculizumab
AO GENERIUM
Paroxysmal Nocturnal Hemoglobinuria
12/22
05/23
NCT05982938: Danicopan Early Access Program

Available
N/A
NA
Danicopan, ALXN2040
Alexion Pharmaceuticals, Inc.
Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
 
 
ChiCTR2300067949: The real world study of Eculizumab for paroxysmal nocturnal hemoglobinuria treatment in China

Not yet recruiting
N/A
10
 
Eculizumab
West China Hospitai, Sichuan University; West China Hospitai, Sichuan University, Apply for hospital project funds
paroxysmal nocturnal hemoglobinuria
 
 

Download Options